RRS® HA Eyes ( 12 x 1.5 mL) | Skin Tech Pharma Group (Spain)

Short Description

A CE Class III certified medical-grade periorbital mesotherapy injectable combining non-cross-linked Hyaluronic Acid (5.0 mg/mL) with a targeted biorevitalizing cocktail of vasoactive flavonoids, antioxidants, and depigmenting agents (Ruscus aculeatus, Melilotus officinalis, Troxerutin, Vitamin C, Resveratrol, and Organic Silicon). Engineered specifically for the thin, delicate periorbital envelope, RRS® HA Eyes treats vascular dark circles, lymphatic under-eye bags, superficial tear trough hollows, and periorbital fine lines—activating microcirculatory drainage, lightening dyschromia, and smoothing crepey skin without hydrophilic swelling or Tyndall effect.

Detailed Description

RRS® HA Eyes is a sterile, non-pyrogenic, absorbable intradermal injectable manufactured in Spain by Skin Tech Pharma Group (Aesthetic Dermal). Operating under strict European medical device directives (CE 1014), it is formulated to address the multifactorial nature of periorbital aging—where vascular congestion, lymphatic stagnation, skin thinning, and pigment accumulation intersect in an anatomically vulnerable space.

The formulation utilizes a multi-targeted biological matrix:

1. Physiological Hyaluronic Acid Base (5.0 mg/mL): Uncross-linked, non-animal bio-fermented sodium hyaluronate replenishes the extracellular matrix of the infraorbital dermis. It restores hydraulic balance, smooths superficial dehydration crinkles, and acts as a biocompatible delivery vehicle for active bio-nutrients without causing excessive water retention or malar festooning.

2. Vasoactive & Lymphatic Drainage Complex (Anti-Bag Action):

   • Ruscus Aculeatus (Butcher’s Broom Extract): Rich in ruscogenins, it acts as a selective venotonic that strengthens capillary walls, reduces microvascular hyperpermeability, and limits transudate pooling.

   • Melilotus Officinalis (Sweet Clover Extract): Delivers natural coumarins that stimulate lymphatic motoricity and macrophage proteolysis, accelerating the clearance of protein-rich fluid from stagnant under-eye bags.

   • Troxerutin & Hesperidin Methyl Chalcone: Bioflavonoids that reinforce endothelial cell junctions, reduce erythrocyte extravasation, and decrease capillary fragility.

3. Depigmenting & Antioxidant Shield (Dark Circle Resolution):

   • Vitamin C & Resveratrol: Neutralize free radicals induced by UV and oxidative stress, suppress melanin overproduction, and lighten hemosiderin deposits caused by extravasated red blood cells.

   • Flavonoids (Naringin, Quercetin, Polyphenols): Inhibit collagenase and elastase enzymes while reducing localized neurogenic inflammation.

4. Dermal Redensifying Matrix (Organic Silicon & Peptides):

   • Organic Silicon (Silanol): Stimulates fibroblast proliferation and stabilizes structural glycosaminoglycan (GAG) networks, thickening the translucent periorbital skin to help conceal underlying dark vascular beds.

Treatment Areas & Indications

• Infraorbital Dark Circles (Periorbital Dyschromia):

  • Vascular Dark Circles: Bluish, purplish, or red discoloration caused by sluggish capillary microcirculation and thin, translucent lower eyelid skin

  • Pigmentary Dark Circles: Brownish epidermal and dermal melanin accumulation around the eye socket

  • Structural Shadowing: Visual darkening accentuated by early tear trough hollows

• Lymphatic Under-Eye Bags & Morning Puffiness:

  • Fluid retention and edematous swelling of the lower eyelids secondary to poor lymphatic return

  • Post-sleep periorbital congestion

• Lower Eyelid & Lateral Canthal Skin Aging:

  • Crepey, paper-thin cutaneous texture and superficial dehydration crinkles

  • Dynamic and fine static lateral canthal lines (crow’s feet)

• Pre- & Post-Blepharoplasty Optimization:

  • Conditioning delicate eyelid tissue prior to surgical blepharoplasty

  • Managing residual post-operative micro-edema and bruising

Key Clinical Advantages

• CE Class III Medical Device Certification: Manufactured under rigorous European pharmaceutical directives (CE 1014), guaranteeing safety and batch purity for direct periorbital intradermal injection.

• Zero Malar Festoon / Edema Risk: Formulated with non-cross-linked HA combined with lymphatic draining botanicals, eliminating the chronic fluid retention often seen with cross-linked BDDE gel fillers.

• Zero Tyndall Discoloration: Integrates transparently into the tissue, leaving no blue discoloration even when deposited superficially in the thin lower eyelid.

• Dual Action (Decongestion + Thickening): Concurrently clears stagnant lymphatic fluid and thickens the dermal barrier to obscure deep underlying orbital vasculature.

• Versatile Delivery Profile: Compatible with precision 32G/34G micro-papular needles, multi-injector mesotherapy devices, or blunt-tip microcannulas.

Clinical Administration & Delivery Protocols

Technique	Recommended Instrument	Injection Plane	Administration Method
Micro-Papular Needle (Standard)	32G or 34G x 4 mm micro-meso needle	Superficial to mid-dermis (0.5–1.0 mm depth)	Micro-boluses of 0.01–0.02 mL per point, spaced 2–4 mm apart along the infraorbital rim and crow’s feet (approx.
	0.5–0.75 mL per eye)	Blunt Microcannula (Advanced)	30G or 27G x 25 mm blunt cannula	Sub-orbicularis oculi / deep subcutaneous plane	Single lateral entry at the zygomatic arch; retrograde linear fan distribution across the infraorbital margin	Microneedling / MTS	Automated microneedling pen	Epidermal-dermal junction (0.25–0.5 mm depth)	Gentle transdermal micro-channeling around the orbital rim (avoiding mobile upper eyelid)

• Standard Clinical Protocol: 4 to 6 sessions spaced 1 to 2 weeks apart.

• Maintenance Schedule: 1 session every 3 to 4 months to preserve microvascular and lymphatic tone.

Technical Specifications

Parameter	Specification
Product Classification	Injectable Periorbital Biorevitalizer / CE Class III Medical Device
Manufacturer / Origin	Skin Tech Pharma Group / Aesthetic Dermal (Girona, Spain)
Hyaluronic Acid Profile	Non-cross-linked sodium hyaluronate (5.0 mg/mL / 7.5 mg per ampoule)
Active Biorevitalizing Complex	27.3 mg/mL solution: Ruscus aculeatus, Melilotus officinalis, Troxerutin, Escin, Hesperidin, Vitamin C, Resveratrol, Organic Silicon, Polyphenols
Lidocaine Content	Lidocaine-free (compatible with pre-procedural topical anesthetic cream)
Packaging Presentation	Box of 4 ampoules x 1.5 mL (6.0 mL total) or Clinic Pack of 12 ampoules x 1.5 mL (18.0 mL total)
Target Injection Planes	Superficial dermis, epidermal-dermal junction, or sub-orbicularis plane
Papule Resolution Time	Typically flattens and absorbs within 12 to 24 hours post-injection
Expected Clinical Duration	4 to 6 months cumulative improvement following a complete series
Storage Instructions	Store between 2°C and 30°C (36°F to 86°F); protect from direct heat, sunlight, and freezing
Regulatory Category	CE-marked Class III Medical Device (CE 1014) / Prescription Only (Rx)

Comparative Benchmark: Leading Periorbital Injectables

Feature	RRS® HA Eyes (Skin Tech)	Jalupro® Young Eye (Prof. Derma)	Lumi Eyes (Dermagen)	PhilArt Eye (Croma)
Primary Active Mechanism	Non-cross HA + Ruscus / Melilotus flavonoids	Bi-density HA + 7 Amino Acids + 3 Peptides	Salmon Polynucleotide (PDRN 2 mg/mL)	High-purification Polynucleotide (PN 15 mg/2 mL)
Target Focus	Vascular dark circles, lymphatic puffiness & bags	Structural thinning, ligament descent, accordion wrinkles	Cellular DNA repair, brightening, micro-lines	Fibroblast biostimulation, skin thickening, elasticity
Anti-Puffiness Action	Very High (Venotonic & lymphatic drainers)	Moderate (Acetyl Tetrapeptide-5)	Low (Pure regenerative DNA)	Low (Pure regenerative PN)
Presentation	4 x 1.5 mL ampoules	1 x 1.0 mL pre-filled syringe	1 x 1.0 mL pre-filled syringe	1 x 2.0 mL pre-filled syringe
Regulatory Status	CE Class III Injectable	CE Class III Injectable	CE / KFDA Certified	CE Class III Injectable

Professional Advisory: RRS® HA Eyes is a CE Class III medical device intended strictly for certified aesthetic physicians, dermatologists, and plastic surgeons trained in periorbital anatomy and micro-injection techniques. Injection inside the orbital septum, into herniated retroseptal fat pads, or directly intravascularly is strictly contraindicated. Patients should avoid aspirin, NSAIDs, and anticoagulants for 48 hours prior to treatment to minimize periorbital petechiae and bruising.